CVP @ National Center for Advancing Translational Sciences (NCATS) Proud to share that CVP and our new Atlas Research colleagues have been awarded a 2 year contract to support the National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR). We will be supporting the IDeaS (Impact of Rare Diseases on Patients and Healthcare Systems) pilot program providing computational tools, methodologies, and analysis to analyze large healthcare system datasets for the prevalence, healthcare utilization, and cost of undiagnosed and misdiagnosed rare diseases. Our team, along with Professor Keith Crandall, the founding director of the Computational Biology Institute at George Washington University, and his team will be analyzing healthcare data to develop predictive models that can be applied to better identify cases where an individual may be experiencing a rare disease.
Congratulations. Good to hear of CVP's continuing success. 🎈 🎉 🎈
This is a great success and I’m excited to see the impact of this body of work. Amazing!
Peter my friend Jim Laflamme has been working the pharmaceutical aspect of this issue. Let me know if you’d like an intro.
Principal at LDN Consulting, LLC
2yThis is a very important project. I’m sure many people will benefit from this work.